Oncology Nursing Drug Handbook

Caring for cancer patients

Free · In‑App Purchases · Designed for iPad

Essential drug reference for oncology nurses. Access sample content free, then subscribe for the latest drug updates, care tips, and safe chemo guidance. "Try before you buy" - Download the FREE App, which includes sample content. An in-App purchase is required to unlock all content. Created especially for nurses caring for patients with cancer, the 2020-2021 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. This essential resource provides valuable information on effective symptom management, patient education, and chemotherapy administration. Completely revised and updated, the 2020-2021 Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for drugs recently approved by the FDA. Key Features * Provides valuable information on effective symptom management, patient education, and chemotherapy administration. * Completely revised and updated, includes separate chapters on molecular and immunologic/biologic targeted therapies * Provides fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer * Offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs * New drugs include: apalutamide (Erleada™), calaspargase pegol-mknl (Asparlas™), Daunorubicin and cytarabine liposome for injection (Vyxeos®), glucarpidase (Voraxaze®), alpelisib (Piqray®), binimetinib (Mektovi®), dacomitinib (Vizimpro®), Duvelisib (Copiktra®), encorafenib (Braftovi®), erdafitinib (Balversa™), lorlatinib (Lorbrena®), anakinra (Kineret®), baricitinib (Olumiant®), sarilumab (Kevzara®), aprepitant injectable emulsion (Cinvanti®), granisetron hydrochloride extended-release injection (Sustol®), letermovir (Prevymis™), omadacycline (Nuzyra™), meropenem/vaborbactam (Vabomere™), Plazomicin (Zemdri™), baloxavir marboxil (Xofluza™), imipenem/cilastatin sodium/relebactam (Recarbrio™), eravacycline (Xerava™), delafloxacin (Baxdela™) No internet connection is required to access the content after the initial download. Find information quickly using powerful SmartSearch technology. Search part of term for those hard to spell medical terms. Content licensed from printed ISBN 10: 1284171329 Content licensed from printed ISBN 13: 978-1284171327 SUBSCRIPTION : Please choose an auto renewable subscription plan to receive content access & continuous updates. Your subscription automatically renews as per your plan, so you always have the latest content. Yearly auto-renewing payments - $69.99 Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user & auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable. If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-30000 Privacy Policy-https://www.skyscape.com/terms-of-service/privacypolicy.aspx Terms and Conditions-https://www.skyscape.com/terms-of-service/licenseagreement.aspx Editor(s): Gail M. Wilkes, MS, APRN-BC, AOCN; Margaret Barton-Burke, PhD, RN, FAAN; Publisher: Jones & Bartlett Learning

  • 4.8
    out of 5
    4 Ratings

- Minor Bug Fixes

The developer, Skyscape Medpresso Inc, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy .

  • Data Used to Track You

    The following data may be used to track you across apps and websites owned by other companies:

    • Identifiers
  • Data Not Linked to You

    The following data may be collected but it is not linked to your identity:

    • User Content
    • Search History
    • Identifiers
    • Usage Data
    • Diagnostics

Privacy practices may vary, for example, based on the features you use or your age. Learn More

The developer has not yet indicated which accessibility features this app supports. Learn More

  • Seller
    • Skyscape Medpresso Inc
  • Size
    • 156.8 MB
  • Category
    • Medical
  • Compatibility
    Requires iOS 13.0 or later.
    • iPhone
      Requires iOS 13.0 or later.
    • iPad
      Requires iPadOS 13.0 or later.
    • iPod touch
      Requires iOS 13.0 or later.
    • Mac
      Requires macOS 11.0 or later and a Mac with Apple M1 chip or later.
    • Apple Vision
      Requires visionOS 1.0 or later.
  • Languages
    • English
  • Age Rating
    16+
  • In-App Purchases
    Yes
  • Copyright
    • © (c) 1998-2030 Skyscape Medpresso, Inc. All rights reserved.